Abbott Inks 2025’s Largest Bridge Loan to Fund Acquisition

Abbott Laboratories has secured a $20 billion, 364-day bridge loan from Morgan Stanley to finance its acquisition of Exact Sciences Corp — the largest high-grade bridge loan of 2025 and one of the biggest sole committed financings in the past decade. The short-term facility provides immediate deal funding and highlights lenders' capacity to back very large single-bank commitments for major M&A.

Analysis

Abbott Laboratories has secured a $20 billion, 364‑day bridge loan from Morgan Stanley to finance its acquisition of Exact Sciences Corp, described as the largest high‑grade bridge loan of 2025 and one of the largest sole committed financings in the past decade. The single‑bank, short‑dated facility provides immediate deal funding and materially reduces near‑term financing uncertainty for the transaction.

The deal signals strong lender capacity for very large one‑bank commitments and produces a moderately positive, risk‑on market signal (sentiment_score 0.4, market_impact_score 0.35). Per‑ticker sentiment is modestly favorable for Abbott (0.4), slightly positive for Exact Sciences (0.3) and limitedly positive for Morgan Stanley (0.2), reflecting credit exposure and fee/underwriting positioning.

Primary investor risks are the bridge tenor and refinancing execution: Abbott must refinance or replace the facility within 364 days, exposing the company to rate, market‑access and covenant risk that could affect leverage and credit metrics. Investors should watch announced terms of the eventual term financing, any rating‑agency commentary, and Morgan Stanley disclosures on concentration and risk management.

Key Decisions for Investors

• For ABT: view the bridge as reducing immediate deal execution risk but monitor Abbott's leverage trajectory and upcoming term‑financing announcements before adding material exposure
• For EXAS shareholders: the funding increases probability of transaction closure so reassess takeover valuation and regulatory/closing risks rather than trading solely on financing headlines
• For MS investors: recognize potential fee income and increased visibility into large‑ticket origination business but monitor the bank's single‑borrower exposure and capital implications
• Fixed‑income and credit investors should watch Abbott's refinancing price and covenant terms over the next 12 months and consider hedging duration or credit‑spread risk until long‑term financing details are disclosed